MARKET

BDTX

BDTX

Black Diamond Therapeutics, Inc.
NASDAQ
2.130
-0.060
-2.74%
After Hours: 2.130 0 0.00% 16:10 03/26 EDT
OPEN
2.180
PREV CLOSE
2.190
HIGH
2.275
LOW
2.120
VOLUME
663.14K
TURNOVER
--
52 WEEK HIGH
4.940
52 WEEK LOW
1.195
MARKET CAP
122.03M
P/E (TTM)
5.48
1D
5D
1M
3M
1Y
5Y
1D
Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity
Seeking Alpha · 1d ago
Weekly Report: what happened at BDTX last week (0316-0320)?
Weekly Report · 3d ago
Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives
Simply Wall St · 03/18 02:15
Black Diamond Theraptcs Is Maintained at Outperform by Wedbush
Dow Jones · 03/17 12:45
Black Diamond Theraptcs Price Target Raised to $14.00/Share From $13.00 by Wedbush
Dow Jones · 03/17 12:45
Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14
Benzinga · 03/17 12:35
Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush
TipRanks · 03/17 11:51
Piper Sandler Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX)
TipRanks · 03/17 11:35
More
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Webull offers Black Diamond Therapeutics Inc stock information, including NASDAQ: BDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BDTX stock methods without spending real money on the virtual paper trading platform.